Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 9/20 | 0.59 |
| ▸ | MMP1 | P03956 | 8/20 | 0.59 |
| ▸ | MMP13 | P45452 | 8/20 | 0.59 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.52 |
| ▸ | NAMPT | P43490 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7621470 | 0.88 | MMP9 (0.63) | MMP9MMP1MMP13ADAM17NAMPT | |
| SCHEMBL7643562 | 0.88 | MMP9 (0.57) | MMP9MMP1MMP13ADAM17NAMPT | |
| SCHEMBL6931438 | 0.81 | MMP9 (0.75) | MMP9MMP1MMP13ADAM17NAMPT | |
| SCHEMBL6932360 | 0.79 | MMP9 (0.78) | MMP9MMP1MMP13ADAM17NAMPT | |
| SCHEMBL6934254 | 0.79 | MMP13 (0.75) | MMP9MMP1MMP13ADAM17NAMPT | |
| SCHEMBL6934187 | 0.78 | MMP9 (0.61) | MMP9MMP1MMP13ADAM17NAMPT | |
| SCHEMBL6932143 | 0.76 | MMP1 (0.72) | MMP9MMP1MMP13ADAM17NAMPT | |
| SCHEMBL7558889 | 0.76 | MMP9 (0.63) | MMP9MMP1MMP13ADAM17NAMPT | |
| SCHEMBL6930509 | 0.75 | MMP1 (0.51) | MMP9MMP1MMP13ADAM17NAMPT | |
| SCHEMBL6930040 | 0.74 | MMP1 (1.00) | MMP9MMP1MMP13ADAM17NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6441023-B1 | FOR THERAPY OF ARTHRITIS, TUMOR METASTASIS, TISSUE ULCERATION, ABNORMAL WOUND HEALING, PERIODONTAL DISEASE, BONE DISEASE, DIABETES (INSULIN RESISTANCE) AND HIV INFECTION | AMERICAN HOME PRODUCTS CORPORATION | 2002-08-27 | — | — | US | disclosed |
| US-20020032186-A1 | N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors | AMERICAN CYANAMID COMPANY (US) | 2002-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032186-A1 | N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors | MMP12, ADAM33, MMP2 | MMP9 13/4885MMP1 4/4885MMP13 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.